India’s Stance on the TRIPS Waiver for COVID-19 Vaccines: Implications for Global Health Equity and Multilateral Diplomacy
Abstract
The COVID-19 pandemic exposed profound global inequalities in access to life-saving vaccines, diagnostics, and treatments. Against this backdrop, India, alongside South Africa, emerged as a key proponent of a temporary waiver of intellectual property (IP) protections under the World Trade Organization’s (WTO) Agreement on Trade-Related Aspects of Intellectual Property Rights (TRIPS). India’s advocacy reflected both humanitarian imperatives and strategic diplomatic positioning within the multilateral system. This paper critically analyzes India’s stance on the TRIPS waiver proposal, exploring its motivations, its alignment with global health equity, and its implications for India’s evolving role in multilateral diplomacy.
1. Background: The TRIPS Waiver Debate
The TRIPS Agreement governs international standards for IP protections, including patents on pharmaceuticals. While proponents argue it incentivizes innovation, critics contend that strict IP rules hinder timely access to affordable medicines, particularly in low- and middle-income countries (LMICs).
In October 2020, India and South Africa formally proposed at the WTO that member states temporarily waive certain TRIPS provisions related to COVID-19 vaccines, diagnostics, and treatments. The goal was to enable LMICs to produce generic versions, scale up local manufacturing, and address vaccine inequity.
While supported by over 100 WTO members and global health advocates, the proposal faced resistance from high-income countries (notably the U.S., EU, UK, and Switzerland) and pharmaceutical companies, citing concerns over innovation incentives, supply chain bottlenecks, and manufacturing capacities.
2. India’s Motivations: Humanitarian and Strategic Drivers
2.1. Humanitarian and Global South Solidarity
India’s support for the TRIPS waiver aligns with its historical role as a champion of Global South solidarity, echoing its activism during the HIV/AIDS crisis when it challenged Western pharmaceutical monopolies to produce affordable generic antiretrovirals.
- India’s pharmaceutical industry is one of the largest global suppliers of generic medicines, often referred to as the “pharmacy of the developing world.”
- By pushing for the waiver, India positioned itself as a moral advocate for equitable access, emphasizing that pandemics require global public goods, not profit-driven models.
This approach resonates with India’s civilizational ethos of Vasudhaiva Kutumbakam (“the world is one family”) and its constitutional commitment to international cooperation on humanitarian issues.
2.2. Strategic Industrial and Economic Interests
India’s pharmaceutical sector also stood to benefit materially:
- A waiver would unlock opportunities for Indian manufacturers to produce vaccines, treatments, and diagnostics that were otherwise under patent restrictions.
- It would bolster India’s standing in global supply chains, reinforcing its ambition to be a biopharmaceutical hub.
Thus, India’s position was not purely altruistic; it also served industrial policy and strategic economic objectives, amplifying its pharmaceutical footprint in the global South.
2.3. Diplomatic Leadership in Multilateral Forums
India’s proactive stance at the WTO reflects its broader ambition to:
- Reclaim leadership in multilateral negotiations on behalf of developing countries.
- Challenge the asymmetric global health governance architecture, dominated by Western pharmaceutical interests and high-income country agendas.
- Strengthen coalitions such as the Group of 33 (G33) and the Group of 77 (G77), amplifying developing country voices in trade and health diplomacy.
This aligns with India’s evolving narrative as a bridge between the Global South and the Global North.
3. Implications for Global Health Equity
3.1. Advancing Normative Debates on Public Health and IP
India’s advocacy underscored the tension between intellectual property rights and the right to health:
- By foregrounding public health over patents, India contributed to shifting global debates on pharmaceutical monopolies, access, and affordability.
- The TRIPS waiver debate exposed the limitations of mechanisms like the COVAX facility, which, despite promises, failed to deliver timely vaccine equity.
India’s stance thus advanced the normative argument that in times of global crisis, patent protections must yield to humanitarian imperatives.
3.2. Limitations of the Waiver Approach
While the waiver proposal garnered moral and political support, its practical impact was constrained:
- Supply-side bottlenecks (e.g., raw materials, manufacturing know-how, cold chain logistics) limited LMICs’ ability to scale up production even with waived IP.
- The eventual WTO compromise in June 2022 fell short of a full waiver, focusing narrowly on vaccines and excluding treatments and diagnostics, partly due to opposition from major pharmaceutical powers.
This revealed the structural power asymmetries in global trade governance, where even large developing countries like India struggle to push through transformative reforms.
4. Implications for India’s Multilateral Diplomacy
4.1. Enhancing India’s Reputation as a Global South Advocate
India’s leadership on the TRIPS waiver reinforced its image as a normative power that champions the interests of marginalized nations, enhancing its credibility in:
- South–South cooperation platforms, such as BRICS and IBSA.
- Global health diplomacy, positioning India as an alternative to China’s vaccine diplomacy.
This soft power gain strengthens India’s diplomatic leverage in parallel negotiations on World Health Organization (WHO) reforms, pandemic preparedness, and climate-health linkages.
4.2. Strategic Balancing in Global Trade Politics
India’s WTO activism on TRIPS also showcased its capacity for strategic balancing:
- While engaging the U.S. and EU on Indo-Pacific security and climate cooperation, India retained independence on trade and health issues, reflecting multi-alignment.
- It built coalitions with African, Caribbean, and Latin American countries, reinforcing its leadership claims in the Global South.
However, India’s challenge remains to translate such normative leadership into concrete material gains—especially when pushback from entrenched industrial and geopolitical powers persists.
4.3. Expanding India’s Pharma Diplomacy
The TRIPS waiver debate amplified India’s pharmaceutical soft power:
- Initiatives like Vaccine Maitri, under which India supplied millions of doses to LMICs, complemented its WTO advocacy.
- However, domestic COVID-19 surges in 2021 strained India’s vaccine diplomacy, exposing vulnerabilities in balancing domestic and external commitments.
This underscores the need for India to scale up pharmaceutical production, innovation, and supply chain resilience if it aspires to be a sustained leader in global health.
Conclusion: A Normative and Strategic Test Case
India’s support for the TRIPS waiver at the WTO reflects the intersection of normative commitments to global health equity and strategic ambitions in multilateral diplomacy. While the waiver itself has yielded only partial results, India’s leadership has highlighted critical deficiencies in the global health governance system, pushed forward debates on IP and access, and positioned India as a key player in shaping future health and trade regimes.
To build on this momentum, India must invest in domestic pharmaceutical capacity, expand international partnerships, and continue leveraging multilateral platforms to advocate for more just and resilient global systems. The TRIPS episode ultimately serves as a test case for India’s ability to navigate the tensions between moral leadership and realpolitik in the 21st-century global order.
Discover more from Polity Prober
Subscribe to get the latest posts sent to your email.